Anocca
- Biotech or pharma, therapeutic R&D
Anocca leverages its deep-tech cell-based platform and in-house cGMP capability to discover, develop and manufacture novel TCR-T product libraries at scale for the treatment of solid tumor cancers and other serious diseases, including autoimmune and infectious disease. The company's oncology pipeline comprises over 40 high value TCR-T assets that span a wide range of cancer targets and HLA restrictions. The most advanced TCR-T progam, targeting KRAS G12V in pancreatic cancer is starting a phase 1/2a trial in Europe, following CTA approval in March 2025.
Based near Stockholm in Sweden, Anocca is privately held and employs a team of over 130 talented individuals.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}